Safe use of statins: focus on muscle toxicity

References

• Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke. 2002;33:2337–2341.10.1161/01.str.0000034125.94759.41
   PubMed Web of Science ®Google Scholar
• Huerta-Alardin AL, Varon J, Marik PE. Bench-to-bedside review: rhabdomyolysis an overview for clinicians. Crit. Care. 2005;9:158–169.
   PubMed Web of Science ®Google Scholar
• Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: pathophysiology and diagnosis. Eur. J. Intern. Med. 2007;19:90–100.10.1016/j.ejim.2006.09.020
   Web of Science ®Google Scholar
• Chavez LO, Leon M, Einav S, et al. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit. Care. 2016;20:135. doi:10.1186/s13054-016-1314-5.
   PubMed Web of Science ®Google Scholar
• Bagley WH, Yang H, Shah KH. Rhabdomyolysis. Intern. Emerg. Med. 2007;2:210–218.10.1007/s11739-007-0060-8
   PubMed Web of Science ®Google Scholar
• Chen CY, Lin YR, Zhao LL, et al. Clinical spectrum of rhabdomyolysis presented to pediatric emergency department. BMC Pediatr. 2013;13:134. doi:10.1186/1471-2431-13-134.
   Web of Science ®Google Scholar
• Chatzizisis YS, Misirli G, Hatzitolios AI, et al. The syndrome of rhabdomyolysis: complications and treatment. Eur. J. Intern. Med. 2008;19:568–574.10.1016/j.ejim.2007.06.037
   PubMed Web of Science ®Google Scholar
• Antons KA, Williams CD, Baker SK, et al. Clinical perspectives of statin-induced rhabdomyolysis. Am. J. Med. 2006;119:400–409.10.1016/j.amjmed.2006.02.007
   PubMed Web of Science ®Google Scholar
• Hadjis T, Grieff M, Lockhat D, et al. Calcium metabolism in acute renal failure due to rhabdomyolysis. Clin. Nephrol. 1993;39:22–27.
   Web of Science ®Google Scholar
• Vanholder R, Sever MS, Erek E, et al. Rhabdomyolysis. J. Am. Soc. Nephrol. 2000;11:1553–1561.
   PubMed Web of Science ®Google Scholar
• Khan FY. Rhabdomyolysis: a review of the literature. Neth. J. Med. 2009;67:272–283.
   PubMed Web of Science ®Google Scholar
• Schlattner U, Tokarska-Schlattner M, Wallimann T. Mitochondrial creatine kinase in human health and disease. Biochim. Biophys. Acta. 2006;1762:164–180.10.1016/j.bbadis.2005.09.004
   PubMed Web of Science ®Google Scholar
• Zhang MH. Rhabdomyolosis and its pathogenesis. World J. Emerg. Med. 2012;3:11–15.10.5847/wjem.j.issn.1920-8642.2012.01.002
   Google Scholar
• Boutaud O, Roberts LJ 2nd. Mechanism-based therapeutic approaches to rhabdomyolysis-induced renal failure. Free Radical Biol. Med. 2011;51:1062–1067.10.1016/j.freeradbiomed.2010.10.704
   PubMed Web of Science ®Google Scholar
• Poels PJ, Gabreëls FJ. Rhabdomyolysis: a review of the literature. Clin. Neurol. Neurosurg. 1993;95:175–192.10.1016/0303-8467(93)90122-W
   PubMed Web of Science ®Google Scholar
• Brumback RA, Feeback DL, Leech RW. Rhabdomyolysis in childhood: a primer on normal muscle function and selected metabolic myopathies characterized by disordered energy production. Pediatr. Clin. North Am. 1992;39:821–858.10.1016/S0031-3955(16)38377-8
   Web of Science ®Google Scholar
• Criddle LM. Rhabdomyolysis. pathophysiology, recognition, and management. Crit. Care Nurse. 2003;23:14–22.
   PubMedGoogle Scholar
• Torres PA, Helmestetter JA, Kaye AM, et al. Rhabdomyolysis: pathogenesis, diagnosis, and treatment. Ochsner J. 2014;15:58–69.
   Web of Science ®Google Scholar
• Knochel JP. Mechanisms of rhabdomyolysis. Curr. Opin. Rheumatol. 1993;5:725–731.10.1097/00002281-199305060-00006
   PubMedGoogle Scholar
• Sauret JM, Marinides G, Wang GK. Rhabdomyolysis. Am. Fam. Physician. 2002;65:907–912.
   PubMed Web of Science ®Google Scholar
• Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine (Baltimore). 1982;61:141–152.10.1097/00005792-198205000-00002
   PubMed Web of Science ®Google Scholar
• Lane JT, Boudreau RJ, Kinlaw WB. Disappearance of muscular calcium deposits during resolution of prolonged rhabdomyolysis-induced hypercalcemia. Am. J. Med. 1990;89:523–525.10.1016/0002-9343(90)90385-Q
   Web of Science ®Google Scholar
• Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N. Engl. J. Med. 2009;361:62–72.10.1056/NEJMra0801327
   PubMed Web of Science ®Google Scholar
• Petejova N, Martinek A. Acute kidney injury due to rhabdomyolysis and renal replacement therapy: a critical review. Crit. Care. 2014;18:224. doi:10.1186/cc13897.
   PubMed Web of Science ®Google Scholar
• Zimmerman JL, Shen MC. Rhabdomyolysis. Chest. 2013;144:1058–1065.10.1378/chest.12-2016
   PubMed Web of Science ®Google Scholar
• Shimada M, Dass B, Ejaz AA. Paradigm shift in the role of uric acid in acute kidney injury. Semin Nephrol. 2011;31:453–458.10.1016/j.semnephrol.2011.08.010
   PubMed Web of Science ®Google Scholar
• De Vera MA, Bhole V, Burns LC, et al. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br. J. Clin. Pharmacol. 2014;78:684–698.10.1111/bcp.2014.78.issue-4
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Cholesterol treatment trialists’ (CTT) collaborators efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.
   PubMed Web of Science ®Google Scholar
• Marais GE, Larson KK. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. Ann. Intern. Med. 1990;112:228–230.10.7326/0003-4819-112-3-228
   PubMed Web of Science ®Google Scholar
• Oshima Y. Characteristics of drugs-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. food and drug administration. Intern. Med. 2011;50:845–853.10.2169/internalmedicine.50.4484
   PubMed Web of Science ®Google Scholar
• Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann. Intern. Med. 2009;150:858–868.10.7326/0003-4819-150-12-200906160-00009
   PubMed Web of Science ®Google Scholar
• Guyton JR. Benefit versus risk in statin treatment. Am. J. Cardiol. 2006;97:95C–97C.10.1016/j.amjcard.2005.12.016
   PubMed Web of Science ®Google Scholar
• Chang JT, Staffa JA, Parks M, et al. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol. Drug Saf. 2004;13:417–426.10.1002/(ISSN)1099-1557
   PubMed Web of Science ®Google Scholar
• Hoffman KB, Kraus C, Dimbil M, et al. A survey of the FDA’s AERS database regarding muscle and tendon adverse events linked to the statin drug class. Plos One. 2012;7:e42866.10.1371/journal.pone.0042866
   Web of Science ®Google Scholar
• Sakaeda T, Kadoyama K, Okuno Y. Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system. Plos One. 2011;6:e28124.10.1371/journal.pone.0028124
   PubMed Web of Science ®Google Scholar
• Cham S, Evans MA, Denenberg JO, et al. Statin-associated muscle-related adverse effects: a case series of 354 patients. Pharmacotherapy. 2010;30:541–553.10.1592/phco.30.6.541
   PubMed Web of Science ®Google Scholar
• Alsheikh-Ali AA, Ambrose MS, Kuvin JT, et al. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation. 2005;111:3051–3057.10.1161/CIRCULATIONAHA.105.555482
   PubMed Web of Science ®Google Scholar
• Rallidis LS, Fountoulaki K, Anastasiou-Nana M. Review managing the underestimated risk of statin-associated myopathy. Int. J. Cardiol. 2012;159:169–176.10.1016/j.ijcard.2011.07.048
   PubMed Web of Science ®Google Scholar
• Law M, Rudnicka AR. Statin safety: a systematic review. Am. J. Cardiol. 2006;97:52C–60C.10.1016/j.amjcard.2005.12.010
   PubMed Web of Science ®Google Scholar
• Davidson MH, Clark JA, Glass LM, et al. Statin safety: an appraisal from the adverse event reporting system. Am. J. Cardiol. 2006;97:32C–43C.10.1016/j.amjcard.2005.12.008
   PubMed Web of Science ®Google Scholar
• Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N. Engl. J. Med. 2002;346:539–540.10.1056/NEJM200202143460721
   PubMed Web of Science ®Google Scholar
• McKenney JM, Davidson MH, Jacobson TA, et al. National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am. J. Cardiol. 2006;97:89C–94C.10.1016/j.amjcard.2006.02.030
   PubMed Web of Science ®Google Scholar
• Norata GD, Tibolla G, Catapano AL. Statins and skeletal muscles toxicity: from clinical trials to everyday practice. Pharmacol. Res. 2014;88:107–113.10.1016/j.phrs.2014.04.012
   PubMed Web of Science ®Google Scholar
• Iwere RB, Hewitt J. Myopathy in older people receiving statin therapy: a systematic review and meta-analysis. Br. J. Clin. Pharmacol. 2015;80:363–371.10.1111/bcp.12687
   PubMed Web of Science ®Google Scholar
• Antons KA, Williams CD, Baker SK, et al. Clinical perspectives of statin-induced rhabdomyolysis. Am. J. Med. 2006;119:400–409.10.1016/j.amjmed.2006.02.007
   PubMed Web of Science ®Google Scholar
• Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr. Opin. Lipidol. 2007;18:401–408.10.1097/MOL.0b013e32825a6773
   PubMed Web of Science ®Google Scholar
• van Staa TP, Carr DF, O’Meara H, et al. Predictors and outcomes of increases in creatine phosphokinase concentrations or rhabdomyolysis risk during statin treatment. Br. J. Clin. Pharmacol. 2014;78:649–659.10.1111/bcp.2014.78.issue-3
   Web of Science ®Google Scholar
• Raju SB, Varghese K, Madhu K. Management of statin intolerance. Indian J. Endocrinol. Metab. 2013;17:977–982.
   PubMedGoogle Scholar
• Jacobson TA. Toward “pain-free” statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin. Proc. 2008;83:687–700.10.1016/S0025-6196(11)60897-5
   PubMed Web of Science ®Google Scholar
• Katsiki N, Athyros VG, Karagiannis A. Exploring the management of statin intolerant patients: 2016 and beyond. Curr. Vasc. Pharmacol. 2016 Feb 26 [Epub ahead of print].
   Web of Science ®Google Scholar
• Vrablik M, Zlatohlavek L, Stulc T, et al. Statin-associated myopathy: from genetic predisposition to clinical management. Physiol. Res. 2014;63(Suppl 3):S327–S334.
   PubMed Web of Science ®Google Scholar
• Ragia G, Kolovou V, Tavridou A, et al. Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients. Mol. Diagn. Ther. 2014;18:323–331.
   PubMed Web of Science ®Google Scholar
• Kolovou G, Kolovou V, Ragia G, et al. CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin. Genet. Mol. Biol. 2015;38:129–137.10.1590/S1415-4757382220140239
   PubMed Web of Science ®Google Scholar
• Frudakis TN, Thomas MJ, Ginjupalli SN, et al. CYP2D6*4 polymorphism is associated with statin-induced muscle effects. Pharmacogenet. Genomics. 2007;17:695–707.10.1097/FPC.0b013e328012d0a9
   PubMed Web of Science ®Google Scholar
• Zuccaro P, Mombelli G, Calabresi L, et al. Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. Pharmacol. Res. 2007;55:310–317.10.1016/j.phrs.2006.12.009
   PubMed Web of Science ®Google Scholar
• Emmanuele V, López LC, Berardo A, et al. Heterogeneity of coenzyme Q10 deficiency: patient study and literature review. Arch Neurol. 2012;69:978–983.
   PubMed Web of Science ®Google Scholar
• Oh J, Ban MR, Miskie BA, et al. Genetic determinants of statin intolerance. Lipids Health Dis. 2007;6:7. doi: 10.1186/1476-511X-6-7.
   PubMed Web of Science ®Google Scholar
• SEARCH Collaborative Group, Link E, Parish S, et al. SLCO1B1 variants and statin-induced myopathy–a genomewide study. N. Engl. J. Med. 2008;359:789–799.
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on assessment, aetiology and management. Eur. Heart J. 2015;36:1012–1022.10.1093/eurheartj/ehv043
   PubMed Web of Science ®Google Scholar
• Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients —the PRIMO study. Cardiovasc. Drugs Ther. 2005;19:403–414.10.1007/s10557-005-5686-z
   PubMed Web of Science ®Google Scholar
• Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis. 2010;210:337–343.10.1016/j.atherosclerosis.2009.11.033
   PubMed Web of Science ®Google Scholar
• Banach M, Serban C, Ursoniu S, et al. Statin therapy and plasma coenzyme Q10 concentrations–a systematic review and meta-analysis of placebo-controlled trials. Pharmacol. Res. 2015;99:329–336.10.1016/j.phrs.2015.07.008
   PubMed Web of Science ®Google Scholar
• Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin. Proc. 2015;90:24–34.10.1016/j.mayocp.2014.08.021
   PubMed Web of Science ®Google Scholar
• Owczarek J, Jasińska M, Orszulak-Michalak D. Drug-induced myopathies. An overview of the possible mechanisms. Pharmacol. Rep. 2005;57:23–34.
   PubMed Web of Science ®Google Scholar
• Mas E, Mori TA. Coenzyme Q(10) and statin myalgia: what is the evidence? Curr. Atheroscler. Rep. 2010;12:407–413.10.1007/s11883-010-0134-3
   PubMed Web of Science ®Google Scholar
• Khayznikov M, Hemachrandra K, Pandit R, et al. Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin D supplementation. N. Am. J. Med. Sci. 2015;7:86–93.
   PubMed Web of Science ®Google Scholar
• Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert. Opin. Drug Saf. 2015;14:935–955.10.1517/14740338.2015.1039980
   PubMed Web of Science ®Google Scholar
• Banach M, Rizzo M, Toth PP, et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch. Med. Sci. 2015;11:1–23.10.5114/aoms.2015.49807
   PubMed Web of Science ®Google Scholar
• Glueck CJ, Budhani SB, Masineni SS, et al. Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance. Curr. Med. Res. Opin. 2011;27:1683–1690.10.1185/03007995.2011.598144
   PubMed Web of Science ®Google Scholar
• Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, et al. Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients. Int. J. Cardiol. 2015;178:111–116.10.1016/j.ijcard.2014.10.118
   PubMed Web of Science ®Google Scholar
• Katsiki N, Athyros VG, Karagiannis A, et al. Vitamin D deficiency, statin-related myopathy and other links with vascular risk. Curr. Med. Res. Opin. 2011;27:1691–1692.10.1185/03007995.2011.598922
   PubMed Web of Science ®Google Scholar
• Phan K, Gomez YH, Elbaz L, et al. Statin dose in renal failure? Which statin to select? Statin treatment non-adherence and discontinuation: clinical implications and potential solutions. Curr. Pharm. Des. 2014;20:6314–6324.10.2174/1381612820666140620162629
   PubMed Web of Science ®Google Scholar
• Agouridis AP, Nair DR, Mikhailidis DP. Strategies to overcome statin intolerance. Expert. Opin. Drug Metab. Toxicol. 2015;11:851–855.10.1517/17425255.2015.1027685
   PubMed Web of Science ®Google Scholar
• Tziomalos K, Athyros VG, Mikhailidis DP. Statin discontinuation: an underestimated risk? The downside of statin discontinuation in high risk patients. Curr. Med. Res. Opin. 2008;24:3059–3062.10.1185/03007990802469102
   PubMed Web of Science ®Google Scholar